Article may be outdated

This article is 8 days old. Some details may have changed since publication.

The Hindu·2 min read·medium

BDR Pharma to acquire stake in Acme’s oral solid formulations business

T
The Hindu Bureau
BDR Pharma to acquire stake in Acme’s oral solid formulations business
✦AI Summary

BDR Pharma is acquiring a controlling stake in Acme Formulation's oral solid business for $250 million. The deal aims to expand BDR's capabilities in oncology, women's health, and international markets.

Why it matters

This acquisition represents significant consolidation in the pharmaceutical manufacturing sector, specifically within contract development and manufacturing organizations (CDMOs).

✦Dive DeeperCreate a free account to unlock

HYDERABAD BDR Pharma will acquire a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries from its existing shareholders, led by alternative investment firm PAG. The transaction values the business at $250 million, a person in the know of the deal said. BDR Pharma said a key rationale for the acquisition is the addition of complementary capabilities across thyroid products, female sex hormone products and general pharmaceutical products. It aligns with its growth priorities across oncology, critical care and women’s healthcare, while creating opportunities to expand its product offerings in international markets, the company said. “Acme will further strengthen our CDMO platform and add differentiated capabilities.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesshealth
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in